Day: November 24, 2020

137076-54-1, 2-(4,7,10-Tris(2-(tert-butoxy)-2-oxoethyl)-1,4,7,10-tetraazacyclododecan-1-yl)acetic acid is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

A solution of DOTA tri-t-butyl ester (10 mg, 0.017 mmol), HBTU (7.8 mg, 0.021 mmol) and DIEA (6.0 muL, 0.034 mmol) in anhydrous DMF (0.5 mL) was stirred at room temperature under nitrogen for 20 minutes, and treated with the product of Part A (8.7 mg, 0.017 mmol). Stirring was continued for 1 hour and the solution was concentrated under reduced pressure. The residue was dissolved in TFA (1 mL), treated with TIS (10 muL), and stirred for 4 hours. The solution was concentrated under reduced pressure and the residue was purified by HPLC on a Phenomenex Luna C18 column (21.2 x 250 mm) using a 0.9%/min gradient of 0 to 18% acetonitrile containing 0.1% TFA at a flow rate of 20 mL/min. The main EPO product peak eluting at 20.5 minutes was lyophilized to give the title compound as a colorless solid (8.5 mg, 62%, HPLC purity 96%). MS (ESI): 793.5 (40, M+H), 396.9 (100, M+2H); HRMS: Calcd for C37H62N9O10 (M+H): 792.4620; Found: 792.462

137076-54-1, The synthetic route of 137076-54-1 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; BRISTOL-MYERS SQUIBB PHARMA COMPANY; WO2007/5491; (2007); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.54258-41-2,1,10-Phenanthrolin-5-amine,as a common compound, the synthetic route is as follows.

54258-41-2, General procedure: Both compounds were synthesized in the same way. A mixture ofthe appropriate aldehyde [thiophene-2,5-dicarbaldehyde (283 mg,2.02 mmol), furan-2,5-dicarbaldehyde (316 mg, 2.55 mmol)] and5-amino-1,10-phenanthroline [(1091 mg, 5.59 mmol) withthiophene-2,5-dicarbaldehyde, (1458 mg, 7.48 mmol) with furan-2,5-dicarbaldehyde] was refluxed in EtOH (50 mL) containing acatalytic amount of acetic acid for 12 h, giving a suspension. Thereaction mixture was filtered hot, and the solid was washed withEtOH to afford the desired product as a yellow solid.N,N0-[thiophene-2,5-diylbis(methan-1-yl-1-ylidene)]bis(1,10-phenanthroline-5-amine): Yield 926 mg, 92.8%. 1H NMR (400 MHz,CDCl3): d = 7.44 (s, 2H), 7.65 (dd, J = 8.0, 4.4 Hz, 2H), 7.69 (s, 2H),7.72 (dd, J = 8.0, 4.4 Hz, 2H), 8.27 (dd, J = 8.4, 1.6 Hz, 2H), 8.87(dd, J = 8.0, 1.6 Hz, 2H), 8.90 (s, 2H), 9.17 (dd, J = 4.4, 1.6 Hz, 2H),9.26 (dd, J = 4.4, 2.0 Hz, 2H). ESI-MS: m/z = 495.3 [M+H]+. IR mmax(KBr, cm1): 3423 (br), 1590 s, 1563m, 1503w, 1485w, 1423m,1384 s, 1239m, 1204w, 1143w, 1110w, 1060m, 973w, 874w,802w, 743m, 627w, 523w, 414w.

54258-41-2 1,10-Phenanthrolin-5-amine 606970, acatalyst-ligand compound, is more and more widely used in various fields.

Reference£º
Article; Cheng, Feixiang; He, Chixian; Yu, Shiwen; Yin, Hongju; Inorganica Chimica Acta; vol. 462; (2017); p. 43 – 49;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.62937-45-5,D-Prolinamide,as a common compound, the synthetic route is as follows.

62937-45-5, General procedure: A stirred suspension of 2-chloro-N-(1-methyl-1H-imidazol-4-yl)furo[3,2-d]pyrimidin-4-amine (1b) (100 mg, 0.40 mmol), (S)-pyrrolidin-2-ylmethanol (122 mg, 1.20 mmol) in N-Methyl-2-pyrrolidinone (1 mL) was subjected to microwave irradiation at 150 C for 2 h. The reaction mixture was diluted with ethyl acetate (50 mL), washed with brine (2 x 20 mL), dried, filtered and concentrated in vacuum. The crude residue was purified by combiflash (silica gel, 12 g, eluting with chloroform/CMA-80) to afford (S)-(1-(4-((1-methyl-1H-imidazol-4-yl)amino)furo[3,2-d]pyrimidin-2-yl)pyrrolidin-2-yl)methanol (2a) (43 mg, 34 % yield) as a light yellow solid; NMR (300 MHz, DMSO-i) delta 9.90 (s, 1H, D20 exchangeable), 8.00 (d, J = 2.1 Hz, 1H), 7.44 (s, 1H), 7.42 (d, J = 1.4 Hz, 1H), 6.71 (d, J = 2.1 Hz, 1H), 4.94 (s, 1H, D2O exchangeable), 4.13 (s, 1H), 3.83 – 3.69 (m, 1H), 3.64 (s, 3H), 3.62 – 3.49 (m, 1H), 3.48 – 3.23 (m, 2H), 2.07 – 1.83 (m, 4H); MS (ES+): 315.4 (M+l), 337.5 (M+Na), (ES-): 313.4 (M- 1). HPLC purity: 98.70%.

As the paragraph descriping shows that 62937-45-5 is playing an increasingly important role.

Reference£º
Patent; BIOCRYST PHARMACEUTICALS, INC.; KOTIAN, Pravin, L.; BABU, Yarlagadda, S.; KUMAR, V., Satish; ZHANG, Weihe; LU, Peng-Cheng; RAMAN, Krishnan; (747 pag.)WO2018/232094; (2018); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

7328-91-8, 2,2-Dimethylpropane-1,3-diamine is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

A solution of 2,2-dimethyl-1,3-propanediamine (5 mmol) in 10 mL absolute ethanol was added to a solution of 2-hydroxy-4-methoxybenzaldehyde (10mmol) in a three-necked round bottom flask. The resultant yellow solution was refluxed under nitrogen for 5 h. The ligand obtained as yellow microcrystals were filtered off, washed with cold ethanol and dried in a vacuum desiccator over blue silicagel [

7328-91-8, Big data shows that 7328-91-8 is playing an increasingly important role.

Reference£º
Article; Soh, Siti Kamilah Che; Shamsuddin, Mustaffa; Asian Journal of Chemistry; vol. 30; 1; (2018); p. 81 – 84;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.170161-27-0,Tri-tert-butyl 1,4,8,11-tetraazacyclotetradecane-1,4,8-tricarboxylate,as a common compound, the synthetic route is as follows.

General procedure: An excess of anhydrous K2CO3 was added to a solution of di- or triprotected cyclam (1 mmol) in dry CH3CN (50 mL) and then a solution of 2,2′-bis(bromomethyl) biphenyl (1 or 2 mmol) in the same solvent was added. The suspension was kept at reflux with strong stirring for 3-4 days. The resulting mixture was filtered and the solvent was vacuum distilled to give a residue that was purified by column chromatography over silica with CH2Cl2/MeOH as the eluent., 170161-27-0

170161-27-0 Tri-tert-butyl 1,4,8,11-tetraazacyclotetradecane-1,4,8-tricarboxylate 10940041, acatalyst-ligand compound, is more and more widely used in various fields.

Reference£º
Article; Burguete, M. Isabel; Clares, M. Paz; Garcia-Espana, Enrique; Luis, Santiago V.; Querol, Manel; Marti-Centelles, Vicente; Tetrahedron; vol. 67; 25; (2011); p. 4655 – 4663;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.103946-54-9,4′-Methyl-[2,2′-bipyridine]-4-carboxylic acid,as a common compound, the synthetic route is as follows.

bpyAc (34.9 mg, 0.163 mmol) and fac-[Re(CO)3(dmso-O)3](PF6)(102.8 mg, 0.157 mmol) were dissolved in dry acetone (10 mL).The mixture was stirred at reflux for 4 h under argon. The solutionwas concentrated at ca. 2 mL and the precipitation of the productwas induced by slow diffusion of diethyl ether. A pure yellowpowder was isolated by filtration and washed with ether. Yield83 mg, 0.117 mmol (75%). Anal. Calc. for C17H16F6N2O6PReS(Mw = 707.56): C, 28.86; H, 2.28; N, 3.96; S, 4.53. Found: C,28.97; H, 2.35; N, 3.78; S, 4.62%. 1H NMR (d, 500 MHz, CD3NO2):9.31 (d, 3J60,50 = 5.6 Hz, 1H, H60), 8.99 (d, 3J6,5 = 5.6 Hz, 1H, H6), 8.92(s, 1H, H30), 8.52 (s, 1H, H3), 8.21 (d, 3J50,60 = 5.6 Hz, 1H, H50), 7.66(d, 3J5,6 = 5.5 Hz, 1H, H5), 2.67 (s, 3H, -CH3), 2.63 (s, 3H, -CH3(dmso)),2.61 (s, 3H, -CH3(dmso)). 1H NMR (d, 500 MHz, dmso-d6): 9.25 (d,3J60,50 = 5.5 Hz, 1H, H60), 9.04 (s, 1H, H30), 8.96 (d, 3J6,5 = 5.6 Hz, 1H,H6), 8.94 (s, 1H, H3), 8.14 (d, 3J50,60 = 5.7 Hz, 1H, H50), 7.69 (d,3J5,6 = 5.2 Hz, 1H, H5), 4.02 (s, 1H, -OH), 2.59 (s, 3H, -CH3). 13CNMR (d, 126 MHz, CD3NO2): 196.50 (s, COfac), 196.35 (s, COfac),191.30 (s, COfac), 164.35 (s, -COOH), 157.39 (s, C20), 154.89 (s,C40), 154.59 (s, C2), 154.25 (s, C60), 152.68 (s, C6), 142.04 (s, C4),128.94 (s, C5), 126.74 (s, C50), 125.19 (s, C3), 123.03 (s, C30), 37.64(d, 2C, -CH3(dmso)), 20.41 (s, -CH3). Selected IR bands (cm1, KBrpellets): 2029 (mCOfac), 1916 (mCOfac), 1710 (mCOacid), 947 (mSO),842 (mP-F), 558 (mP-F). UV-Vis (kmax, nm, CH2Cl2): 295, 318sh,331sh, 375., 103946-54-9

As the paragraph descriping shows that 103946-54-9 is playing an increasingly important role.

Reference£º
Article; Cavigli, Paolo; Balducci, Gabriele; Zangrando, Ennio; Demitri, Nicola; Amati, Agnese; Indelli, Maria Teresa; Iengo, Elisabetta; Inorganica Chimica Acta; vol. 439; (2016); p. 61 – 68;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

4479-74-7, 2,2-Bipyridine-6,6-dicarboxylic Acid is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

General procedure: A mixture of 2,2?-bipyridine-6,6?-dicarboxylic acid (244 mg,1.0 mmol), Ru(DMSO)4Cl2 (484 mg, 1.0 mmol), and Et3N (0.8ml) in methanol (10 ml) was degassed with N2 and refluxed for 4 h. The solution changed from bright yellow to dark before the appearance of a brown precipitate. After cooling to room temperature, the precipitate was filtered and washed with methanol (10 ml ¡Á 3) and ether (10 ml ¡Á 3) to get a reddish-brown powder. The powder was mixed with an excess of 4,4?-bipyridine in methanol (20 ml) and heated to reflux for 2 h. The solvent was removed and the resulted residue was re-dissolved in dichloromethane, washed with water to remove triethylamine hydrochloride, and dried over MgSO4 under N2. After purification by column chromatography on silica gel with dichloromethane-methanol (20:1 to 1:1, V:V) as eluent, complex1 was obtained as a dark red solid. Yield: 229 mg (35%).

4479-74-7, The synthetic route of 4479-74-7 has been constantly updated, and we look forward to future research findings.

Reference£º
Article; Jiang, Yi; Li, Fei; Huang, Fang; Zhang, Biaobiao; Sun, Licheng; Cuihua Xuebao/Chinese Journal of Catalysis; vol. 34; 8; (2013); p. 1489 – 1495;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

13465-09-3, Indium(III) bromide is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

Step G: tert-Butyl 3-(6-(((tert-butyldimethylsilyl)oxy)methyl)-5-methylpyridin-2-yl)-3-(3-(difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-2,2-dimethylpropanoate. InBr3 (501 mg, 1.41 mmol) was added to a solution of 7-((6-(((tert-butyldimethylsilyl)oxy)methyl)-5-methylpyridin-2-yl)chloromethyl)-3-(difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridine (2.2 g, 4.7 mmol), ((1-(tert-butoxy)-2-methylprop-1-en-1-yl)oxy)trimethylsilane (10.2 g, 47.1 mmol), and dichloromethane (40 mL) under N2. The resultant mixture was stirred at room-temperature for 5 days, poured it into water (30 mL) and extracted with dichloromethane (3*). These extractions resulted in several fractions that were combined, washed with brine (30 mL), dried over anhydrous Na2SO4, filtered, and concentrated to dryness under reduced pressure. The residue was purified by flash chromatography (eluent:petroleum ether/ethyl acetate; 1:0 to 3:2, gradient) to afford the title compound (1.3 g, 48%), which was used in the next step without further purification. MS (ESI): mass calcd. for C30H44F2N4O3S 574.3 m/z found 575.3 [M+H]+., 13465-09-3

13465-09-3 Indium(III) bromide 167051, acatalyst-ligand compound, is more and more widely used in various fields.

Reference£º
Patent; Janssen Pharmaceutica NV; Barbay, J. Kent; Chai, Wenying; Hirst, Gavin C.; Kreutter, Kevin D.; Kummer, David A.; McClure, Kelly J.; Nishimura, Rachel T.; Shih, Amy Y.; Venable, Jennifer D.; Venkatesan, Hariharan; Wei, Jianmei; (501 pag.)US2020/55874; (2020); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.170161-27-0,Tri-tert-butyl 1,4,8,11-tetraazacyclotetradecane-1,4,8-tricarboxylate,as a common compound, the synthetic route is as follows.

To a solution of tri-Boc cyclam S7 (3.80 g, 7.59 mmol) in anhydrous CH3CN (160 mL) were added Na2CO3 (0.956 g, 9.10 mmol) and ethyl bromoacetate (1.00 mL, 9.02 mmol). The reaction mixture was stirred at reflux under Ar overnight. The insoluble salts were filtered, and the filtrate was concentrated under reduced pressure. The residuewas purified by flash column chromatography (silica gel, EtOAc:hexane = 1:2 rampingto 1:1) to give S9 as a white foam (4.06 g, 91%). RF (EtOAc:hexane = 1:1) 0.67. IRvmax/cm 2974, 2933, 2869, 1737, 1685, 1465, 1411, 1366, 1292, 1240, 1154, 1032,772, 731. 1H NMR (300 MHz, CDCI3) 5 1.26 (t, 3H, J 7.2, COOCH2CH3), 1 .46 (5, 27H, 3 C(CH3)3), 1.60-1.78 (m, 2H, CH2CH2CH2), 1.85-2.00 (m, 2H, CH2CH2CH2), 2.60-2.72(m, 2H, CH2N(CH2COOCH2CH3)CH2), 2.80-2.90 (m, 2H, CH2N(CH2COOCH2CH3)CH2),3.22-3.65 (m, 14H, 3 x CH2N(Boc)CH2 & NCH2COOCH2CH3), 4.14 (q, 2H, J 7.2, COOCH2CH3). ?3C NMR (75 MHz, CDCI3) 5 14.2, 27.0, 28.4, 45.2, 46.8, 47.1, 47.3,48.3, 51.8, 52.9, 53.6, 55.3, 60.1, 79.4, 155.4, 155.6, 170.9 (twelve carbon signals overlapping or obscured). MS (ESI) m/z 587.0 ([M+H], 6%), 609.1 ([M+Na], 100%), 1194.9 ([2M+Na], 47%). The spectroscopic data were in agreement with those in the literature.27?28, 170161-27-0

The synthetic route of 170161-27-0 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; THE UNIVERSITY OF SYDNEY; RUTLEDGE, Peter; TODD, Matthew; TRICCAS, James Anthony; WO2014/153624; (2014); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.109073-77-0,[2,2′-Bipyridine]-4,4′-diyldimethanol,as a common compound, the synthetic route is as follows.

This reaction was performed under nitrogen atmosphere using freshly distilled,anhydrous solvents and reagents. Thionyl chloride (1.02 mL,14.0 mmol) was diluted with CH2Cl2 (15 mL) and the solution,cooled to 0 C, was added dropwise via syringe over 2 min to a cold(0 C) solution of lipoic acid (1.94 g, 9.36 mmol) in CH2Cl2 (25 mL).The solution was stirred at 0 C for 1 h, then the ice bath was removedand the solution was allowed to reach room temperature over 1 h. The solvents were removed in vacuo to leave lipoylchloride as a pale brown residue. This was dissolved in toluene (25 mL) and added dropwise over 30 min to a flask charged witha cold (0 C) solution of 3 (200 mg, 0.936 mmol) and Et3N (4.50 mL)in toluene (20 mL). The reaction was stirred overnight. Water(75 mL) was added, resulting in the formation of a brown precipitate.The mixture was filtered, the solid was discarded, and the organic layer was washed with water (250 mL) and dried over anhydrous Na2SO4. The solvent was removed in vacuo, to obtaina yellow crude product. This was purified by column chromatography using neutral alumina and hexane/ethyl acetate (2:1). After the less polar fraction (mostly lipoic acid) was separated, the eluentwas changed to hexane/ethyl acetate (1:4) to collect the fractions with the product. The solvent was removed in vacuo and theproduct was obtained as a yellow solid, 109073-77-0

As the paragraph descriping shows that 109073-77-0 is playing an increasingly important role.

Reference£º
Article; Kopecky, Andrew; Liu, Guangliang; Agushi, Ardian; Agrios, Alexander G.; Galoppini, Elena; Tetrahedron; vol. 70; 36; (2014); p. 6271 – 6275;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI